Trevi Therapeutics price target raised to $11 from $7 at Leerink

Leerink analyst Faisal Khurshid raised the firm’s price target on Trevi Therapeutics (TRVI) to $11 from $7 and keeps an Outperform rating on the shares. The firm views data from the RIVER study in refractory chronic cough as a “clear win” for Trevi. The analyst continues to see Haduvio as a “best-in-disease drug with robust efficacy” across a broad refractory chronic cough opportunity. Leerink says additional detail in the call confirmed Haduvio demonstrated robust efficacy across endpoints, including in both moderate and severe patients.